Skip to main content

Targeting Cell Cycle to Suppress Cancer Aggressiveness

Buy Article:

$68.00 + tax (Refund Policy)

Background: Failure of cell division control due to mutations leading to inactivation or over activation of regulatory proteins is the leading cause of cancer development. Several mitogens and growth factors have been found to regulate cancer cell cycle progression. However, all signalling pathways converge to the cell cycle machinery and thus disruption of cell cycle control offers an attractive therapeutic target for the treatment of cancer.

Method: We undertook a comprehensive search of bibliographic databases through PubMed and selected the most relevant and appropriate peer-reviewed research articles.

Results: There has been a breakthrough in identification of the cell cycle regulatory molecules and elucidation of their roles in subtle adjustment of the balance between proliferation and apoptosis of cancer cells. This review will shed light on the current understanding of the regulation of the cell cycle pathway links and the feasibility of targeting cell cycle for fighting metastatic cancer.

Conclusion: There are cross-talks among the diverse neoplastic cell types acting together on cell cycle to ensure survival, growth and metastasis, by inhibiting apoptosis, promoting angiogenesis, and avoiding immune system. Approaches should be undertaken to synergistically block the activation of the interconnected pathways for effective cancer therapy.

Keywords: CDK; Cancer; cell cycle; check points; cyclins; drug targets; extraribosomal functions; genomic instability; immunomodulatory microRNAs; metabolic reprogramming; oxidative stress; p53; therapeutics

Document Type: Review Article

Publication date: 01 August 2017

More about this publication?
  • In recent years a breakthrough has occurred in our understanding of the molecular pathomechanisms of human diseases whereby most of our diseases are related to intra and intercellular communication disorders. The concept of signal transduction therapy has got into the front line of modern drug research, and a multidisciplinary approach is being used to identify and treat signaling disorders.

    The aim of this journal is to publish timely in-depth reviews as well as original papers in the field of signal transduction therapy. Thematic issues will also be published to cover selected areas of signal transduction therapy. Coverage of the field will include genomics, proteomics, medicinal chemistry and the relevant diseases involved in signaling e.g. cancer, neurodegenerative and inflammatory diseases.

    Current Signal Transduction Therapy is an essential journal for all involved in drug design and discovery.
  • Editorial Board
  • Information for Authors
  • Subscribe to this Title
  • Ingenta Connect is not responsible for the content or availability of external websites
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content